AEterna Zentaris (AEZS)
(Delayed Data from NSDQ)
$5.35 USD
-0.05 (-0.93%)
Updated Jul 26, 2024 02:51 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
AEterna Zentaris Inc. [AEZS]
Reports for Purchase
Showing records 21 - 40 ( 168 total )
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Macrilen Commercialization Strategy Under Review
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on EU Out-Licensing of Macrilen; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
An Uneventful Q1 With Development Activities to the Fore; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Macrilen Approved in the EU; What''s Next for Aeterna? Higher $5.50 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
A Missed Opportunity in the US; European Approval Expected in 1H19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Anticipating Macrilen''s Launch in the US and Approval in Europe; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Readying Macrilen for US Launch; Looking Ahead to EU Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Potential Macrilen Approval Before Year End Could Attract Acquirers; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Macrilen NDA Resubmitted; Potential Launch in 1Q18; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Focus on Macrilen With Potential Approval in 1Q18; Adjusting PT to $3.00; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Down But Not Out; Revised $7.50 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Macrilen and Zoptrex Phase 3 Study Results in 1Q17; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Looking Ahead to Two Pivotal Study Readouts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Two Major Calalysts in the Near Term; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Building an Oncology Franchise Ahead of Zoptrex; New PT $12.00; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Share Consolidation Complete; New PT $11; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Resolution of Warrant Overhang Removes Capital Structure Uncertainty; New $0.11 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Fundamentally Strong With Pressure From Capital Structure; Revising PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Saizen Promotion Could Generate Better Economics; Reiterate Buy
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: RAMAKANTH S